Skip to main content
Equibles
RCKT logo

RCKT · Rocket Pharmaceuticals, Inc. · Metrics

Track RCKT — free

Use RCKT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RCKT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.34 +0.10 (+4.46%) At close · Oct 20
Russell 2000 member Rebalance outlook locked
Market Cap
$245.90M
Shares
109.77M
Volume · Oct 20 1.89M Avg daily vol (3M) 1.78M

RCKT metrics

73 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.34
Market cap
$245.90M

Price action

20 metrics
Price change (1W)
+1.7%
Price change (30D)
-28.4%
Price change (3M)
-31.2%
Price change (6M)
-36.1%
Price change (YTD)
-33.3%
Price change (1Y)
-41.5%
Trailing year
Price change (5Y)
-91.9%
52-week high
$5.30
52-week low
$2.18
Change from 52-week high
-55.8%
Change from 52-week low
+7.3%
Annualized volatility
67.8%
Annualized volatility (3M)
63.3%
Beta
1.8
RSI (14D)
37.0
Price vs SMA 50
-25.3%
Price vs SMA 200
-33.2%
Avg volume (3M)
1.78M
Relative volume
1.1
Average dollar volume
$5.48M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
109.77M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.7
reciprocal yield 150.0%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-03-27

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$191.64M
Net income (TTM)
−$17.25M
Trailing 12 months
Diluted EPS (TTM)
$-0.17
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.70
EBITDA per diluted share (TTM)
$-1.64
Net income per diluted share (TTM)
$-0.18
Operating cash flow per diluted share (TTM)
$-1.51
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.11
Stock compensation per diluted share (TTM)
$0.28
Book value per share
$2.56

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-4.7%
Return on assets
-4.1%
Debt / equity
0.1
Current ratio
9.2
EBITDA (TTM)
−$184.04M
Free cash flow (TTM)
—
Quick ratio
9.2
Interest coverage
-101.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$262.48M
Latest balance sheet
Cash & equivalents
$224.51M
Total assets
$423.10M
Total debt
$21.27M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$170.27M
Capital expenditures (TTM)
$127,000
R&D (TTM)
$124.37M
SG&A (TTM)
—
Stock compensation (TTM)
$31.78M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
187
13F filer change QoQ
-19
Institutional ownership
92.7%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
49.1%
Private-fund adviser ownership
43.8%
Active holders' share change QoQ
+8.7%
Holder tenure
14.0
Price vs estimated holder cost
-35.3%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.0%

Short interest

3 metrics
Short interest
13.7%
Latest settlement · 6.9 days to cover
Days to cover
6.9d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$432,467
Insider-sentiment score
22 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1281895 CUSIP 77313F106 13F (30d) 14 filings 14 filers Visit website Investor relations